Physioneal 35 Glucose 22,7 mg/ml Clear-Flex Norja - norja - Statens legemiddelverk

physioneal 35 glucose 22,7 mg/ml clear-flex

baxter medical ab - glukosemonohydrat / natriumklorid / kalsiumkloriddihydrat / magnesiumkloridheksahydrat / natriumhydrogenkarbonat / natriumlaktat - peritonealdialysevæske

Physioneal 40 Glucose 22,7 mg/ml Clear-Flex Norja - norja - Statens legemiddelverk

physioneal 40 glucose 22,7 mg/ml clear-flex

baxter medical ab - glukosemonohydrat / natriumklorid / kalsiumkloriddihydrat / magnesiumkloridheksahydrat / natriumhydrogenkarbonat / natriumlaktat - peritonealdialysevæske

Physioneal 40 Glucose 38,6 mg/ml Clear-Flex Norja - norja - Statens legemiddelverk

physioneal 40 glucose 38,6 mg/ml clear-flex

baxter medical ab - glukosemonohydrat / natriumklorid / kalsiumkloriddihydrat / magnesiumkloridheksahydrat / natriumhydrogenkarbonat / natriumlaktat - peritonealdialysevæske

Physioneal 40 Glucose 13,6 mg/ml Clear-Flex Norja - norja - Statens legemiddelverk

physioneal 40 glucose 13,6 mg/ml clear-flex

baxter medical ab - glukosemonohydrat / natriumklorid / kalsiumkloriddihydrat / magnesiumkloridheksahydrat / natriumhydrogenkarbonat / natriumlaktat - peritonealdialysevæske

Tygacil Euroopan unioni - norja - EMA (European Medicines Agency)

tygacil

pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - antibakterielle midler for systemisk bruk, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler. riktig bruk av antibakterielle midler.

Zavicefta Euroopan unioni - norja - EMA (European Medicines Agency)

zavicefta

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibakterielle midler for systemisk bruk, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.

Ceftazidim Fresenius Kabi 2000 mg Norja - norja - Statens legemiddelverk

ceftazidim fresenius kabi 2000 mg

fresenius kabi norge as - halden - ceftazidimpentahydrat - pulver til injeksjons-/infusjonsvæske, oppløsning - 2000 mg

Ceftazidim Fresenius Kabi 1000 mg Norja - norja - Statens legemiddelverk

ceftazidim fresenius kabi 1000 mg

fresenius kabi norge as - halden - ceftazidimpentahydrat - pulver til injeksjonsvæske, oppløsning - 1000 mg

Ceftazidim Fresenius Kabi 500 mg Norja - norja - Statens legemiddelverk

ceftazidim fresenius kabi 500 mg

fresenius kabi norge as - halden - ceftazidimpentahydrat - pulver til injeksjonsvæske, oppløsning - 500 mg

Ceftazidim MIP 1 g Norja - norja - Statens legemiddelverk

ceftazidim mip 1 g

mip pharma gmbh - ceftazidimpentahydrat - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 g